Business Wire

Kweichow Moutai Presents Chinese Enterprise’s ESG Insights at 2025 WEF

24.1.2025 17:49:00 EET | Business Wire | Press release

Share

Wang Li, General Manager of Kweichow Moutai Group, China's top liquor company, was invited to participate in the 2025 World Economic Forum (WEF) Annual Meeting, which officially opened recently, and shared the Moutai solutions on topics such as ESG practices, green and low-carbon development.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250124612942/en/

Wang Li, General Manager of Kweichow Moutai Group, presented Moutai's advanced experience in green technological innovation at the Davos-Caixin CEO luncheon. (Photo: Business Wire)

At the 2025 Davos-Tencent Finance Vision Dinner, Wang explained the ESG development based on Moutai's practices. She said that Moutai adheres to long-termism and high-quality development, integrates the ESG concept into the entire production and operation process. By pursuing sustainable development from three dimensions: harmonious coexistence with nature, sharing of social value, and modernization of self-governance, Moutai accumulates momentum and advantages for future development.

Besides, Wang Li presented Moutai's advanced experience in green technological innovation at the Davos-Caixin CEO luncheon as well. She said that Moutai liquor is the result of adhering to harmonious coexistence between mankind and nature. Kweichow Moutai Group insists on leveraging the innovative power of green technology to support the company's green development, focusing on "energy saving, carbon reduction, emission reduction, and efficiency improvement" to achieve "greening level improvement of the main value chain".

Through the resource utilization, greening and high-end development of the by-products in the liquor industry, Moutai has realized the utilization of its by-products. Looking to the future, Moutai will be committed to applying more innovative power and methods of green technology to maintain the characteristics of its products.

Furthermore, Wang proposed Moutai's carbon reduction solution at the First Movers Coalition Leadership Meeting. Wang said, “The accurate management of the whole chain is an important feature of Moutai's carbon emission management. Moutai accounts for the carbon footprint of the whole life cycle of its products and has formulated targeted programs for the transformation of the energy structure, the reduction and greening of packaging materials, etc.”

Moutai also pays attention to the recycling of post-drinking packages, and plans to start post-drinking package recycling in China's provincial capitals in 2025, with the goal of reducing the carbon emissions of the whole industrial chain by 20% by 2030.

During the WEF, Wang Li will also take part in the “China Night” dialogue, sharing Moutai's wisdom with Chinese and foreign experts on the thinking of Chinese enterprises in coping with the age of intelligence and the shaping of the international image of Chinese enterprises.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250124612942/en/

Contacts

Eason Zhou
Email: evisionsinfo@gmail.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 13:00:00 EEST | Press release

Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat

Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 12:11:00 EEST | Press release

Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/en/ Haleon Health Ambassador on motorbike, equipped with testing kits, samples and diagnostic tools Building capacity to meet rising demand The new site, which is well-positioned in the middle of the country and close to some of India’s most renowned technical colleges, marks an important step in the delivery of Haleon’s Win as One strategy. Win as On

Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 11:56:00 EEST | Press release

Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the intestinal wall, a fundamentally new pharmacological finding. No nausea or side effects observed: No adverse events observed across the 8-subject cohort over one week, cons

Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 11:00:00 EEST | Press release

Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a

Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 11:00:00 EEST | Press release

Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye